Related Experiment Video
Updated: May 15, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Antidepressant use and glycemic control
1Department of Mental Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA. rmojtaba@jhsph.edu
Psychopharmacology
|January 22, 2013
Summary
Antidepressant use did not increase the risk of abnormal blood sugar or undiagnosed diabetes in US adults. Past findings may be due to increased testing in those prescribed antidepressants.
Area of Science:
- Endocrinology
- Psychiatry
- Public Health
Background:
- Previous studies on antidepressant use and glycemic control have yielded inconsistent results.
- Investigating this association is crucial for understanding potential metabolic side effects of common psychiatric medications.
Purpose of the Study:
- To assess the relationship between antidepressant use and glycemic control abnormalities.
- To determine if antidepressant use is linked to undiagnosed diabetes in a US adult population without a prior diabetes diagnosis.
Main Methods:
- Utilized data from the National Health and Nutrition Examination Survey (NHANES) from 2005-2010.
- Examined associations between antidepressant use and measures of HbA1c, fasting blood sugar, and oral glucose tolerance tests.
- Assessed screen-positive diabetes based on established glycemic thresholds.
Main Results:
- No significant association was found between antidepressant use and elevated HbA1c, fasting blood sugar, or impaired glucose tolerance.
- Antidepressant use was not linked to reduced insulin sensitivity or a higher prevalence of screen-positive diabetes.
- These findings remained consistent across various demographic groups, antidepressant types, and body mass index levels.
Conclusions:
- Antidepressant use does not appear to elevate the risk of glycemic abnormalities or undiagnosed diabetes in the general US adult population.
- Discrepancies in prior research may stem from detection bias, where individuals on antidepressants are more frequently screened for diabetes.
Related Concept Videos
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
01:15Hypoglycemia and Glucagon
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...